Desimio Maria Giovanna, Giuliani Erica, Doria Margherita
Laboratory of Immunoinfectivology, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Laboratory of Immunoinfectivology, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Virology. 2017 Oct;510:9-21. doi: 10.1016/j.virol.2017.06.033. Epub 2017 Jul 6.
In pilot HIV-1 eradication studies, patients' immune responses were ineffective at killing viral reservoirs reactivated through latency reversing agents (LRAs) like suberoylanilide hydroxamic acid (SAHA). We hypothesized that T cells harboring reactivated HIV-1 express MIC and ULBP ligands for the activating NKG2D receptor of natural killer (NK) cells. Here, we demonstrated that MICA/B and ULBP2 are induced by SAHA on primary T cells harboring reactivated virus. Using latently HIV-1-infected J-Lat 6.3/8.4/9.2 and J1.1 cell lines, we showed that SAHA reverts latency and, simultaneously, up-regulates MICA/B and ULBP2 acting at the transcriptional level and through ATR activation, thus sensitizing T cells with reactivated virus to NKG2D-mediated killing by NK cells. Moreover, IL-2 and IL-15 potently boosted NKG2D expression and cytotoxicity of NK cells against SAHA-reactivated p24 target cells. Therefore, immunotherapy with cytokines enhancing NKG2D-mediated NK-cell cytotoxicity combined with administration of LRAs up-modulating NKG2D ligands, represents a promising approach towards HIV-1 eradication.
在HIV-1根除的前期研究中,患者的免疫反应在杀死通过诸如辛二酰苯胺异羟肟酸(SAHA)等潜伏期逆转剂(LRA)重新激活的病毒储存库方面无效。我们推测,携带重新激活的HIV-1的T细胞表达天然杀伤(NK)细胞激活型NKG2D受体的MICA和ULBP配体。在此,我们证明SAHA可在携带重新激活病毒的原代T细胞上诱导MICA/B和ULBP2。利用潜伏感染HIV-1的J-Lat 6.3/8.4/9.2和J1.1细胞系,我们表明SAHA可逆转潜伏期,同时在转录水平并通过ATR激活上调MICA/B和ULBP2,从而使携带重新激活病毒的T细胞对NK细胞介导的NKG2D杀伤敏感。此外,IL-2和IL-15可有效增强NK细胞对SAHA重新激活的p24靶细胞的NKG2D表达和细胞毒性。因此,用增强NKG2D介导的NK细胞细胞毒性的细胞因子进行免疫治疗,并联合使用上调NKG2D配体的LRA,代表了一种有前景的HIV-1根除方法。